Related references
Note: Only part of the references are listed.Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetwdmab: A systematic review and meta-analysis
Omar Abdel-Rahman et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Erlotinib: Another Candidate for the Therapeutic Drug Monitoring of Targeted Therapy of Cancer? A Pharmacokinetic and Pharmacodynamic Systematic Review of Literature
Emilie Petit-Jean et al.
THERAPEUTIC DRUG MONITORING (2015)
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients
C. Narjoz et al.
INVESTIGATIONAL NEW DRUGS (2015)
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma
B. Schilling et al.
ANNALS OF ONCOLOGY (2014)
Acute Renal Failure Associated With the New BRAF Inhibitor Vemurafenib
Vincent Launay-Vacher et al.
CANCER (2014)
Exposure-Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma
Masahide Fukudo et al.
CLINICAL PHARMACOKINETICS (2014)
Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
Huixin Yu et al.
CLINICAL PHARMACOKINETICS (2014)
Review of therapeutic drug monitoring of anticancer drugs part two - Targeted therapies
Nicolas Widmer et al.
EUROPEAN JOURNAL OF CANCER (2014)
Vemurafenib significantly decreases glomerular filtration rate
C. Uthurriague et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur et al.
LANCET ONCOLOGY (2014)
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin et al.
LANCET ONCOLOGY (2014)
Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas
E. Regnier-Rosencher et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer
Masahide Fukudo et al.
CLINICAL PHARMACOKINETICS (2013)
The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF 600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
Silvy da Rocha Dias et al.
EUROPEAN JOURNAL OF CANCER (2013)
An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients
Yi Zheng et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2013)
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
Jennifer Arrondeau et al.
INVESTIGATIONAL NEW DRUGS (2012)
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
Vipin Yadav et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
Bo Gao et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
RAF around the Edges - The Paradox of BRAF Inhibitors
Ashani T. Weeraratna
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
Pascaline Boudou-Rouquette et al.
PLOS ONE (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rapid-Learning System for Cancer Care
Amy P. Abernethy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
Bret Wacker et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
